A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2018
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Sep 2018 Planned End Date changed from 27 Apr 2020 to 27 Dec 2020.
- 04 Sep 2018 Planned primary completion date changed from 27 Apr 2019 to 27 Dec 2019.
- 29 Aug 2017 New trial record